<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT00515021</url>
  </required_header>
  <id_info>
    <org_study_id>070183</org_study_id>
    <nct_id>NCT00515021</nct_id>
  </id_info>
  <brief_title>Diurnal Variation of Plasminogen Activator Inhibitor-1</brief_title>
  <official_title>The Effects of Night-time Versus Morning Administration of Eplerenone on the Diurnal Variation of Plasminogen Activator Inhibitor-1</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>Vanderbilt University Medical Center</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
    <collaborator>
      <agency>National Center for Research Resources (NCRR)</agency>
      <agency_class>NIH</agency_class>
    </collaborator>
  </sponsors>
  <source>Vanderbilt University Medical Center</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      To determine if nighttime administration of an aldosterone antagonist would effectively lower&#xD;
      peak plasma Plasminogen Activator Inhibitor-1 (PAI-1) levels more effectively than morning&#xD;
      administration.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Plasminogen activator inhibitor-1, a member of the serine protease inhibitor (serpin)&#xD;
      superfamily, is the principal inhibitor to tissue-type plasminogen activator and&#xD;
      urokinase-type plasminogen activator. Elevated plasma PAI-1 levels, an independent&#xD;
      cardiovascular risk factor, has been shown to be a predictor of recurrent myocardial&#xD;
      infarction (MI). Acute changes in plasma PAI-1 after MI is a predictor of mortality. PAI-1&#xD;
      levels are elevated in the individuals with hypertension, insulin resistance,&#xD;
      hypertriglyceridemia, obesity, and the constellation of risk-factors known as the metabolic&#xD;
      syndrome. PAI-1 is synthesized in the liver, vascular endothelium, vascular smooth muscle,&#xD;
      and visceral adipose tissue. A number of factors have been shown to regulate PAI-1, including&#xD;
      metabolic factors such as insulin, glucose, triglycerides; inflammatory cytokines such as&#xD;
      tumor necrosis factor-α, transforming growth factor-β, interleukin-1, and more notably,&#xD;
      components of the renin-angiotensin-aldosterone system (RAAS), namely angiotensin II and&#xD;
      aldosterone.&#xD;
&#xD;
      PAI-1 also has a diurnal variation with a peak plasma level occurring between 8 and 9 AM that&#xD;
      may help explain why the incidence of acute MI is highest in the morning and why thrombolysis&#xD;
      is least effective at that time. PAI-1's diurnal variation is been shown to be directly&#xD;
      regulated by central and peripheral circadian pacemakers in vitro, and in vivo. Our group has&#xD;
      observed that the diurnal variation of plasma PAI-1 levels is blunted and delayed in blind&#xD;
      individuals who's circadian mechanisms are free running (not controlled by a central&#xD;
      circadian pacemaker) when compared to those whose circadian rhythms are entrained (controlled&#xD;
      by a central circadian pacemaker) (unpublished data), suggesting an additional system may&#xD;
      modulate diurnal variation of PAI-1. As plasma renin activity (PRA) and aldosterone levels&#xD;
      peak earlier than PAI-1 levels, they may be partially responsible. Indeed, continuous&#xD;
      infusion of candesartan eliminated diurnal variation of aortic PAI-1 message expression in&#xD;
      Wistar-Kyoto and spontaneously hypertensive rats, while hydralazine did not.&#xD;
&#xD;
      The use of therapies to modulate plasma PAI-1 levels in human subjects have met with variable&#xD;
      success. Low salt diet was shown to increase plasma PAI-1 levels in normotensive subjects in&#xD;
      a manner that correlated with plasma aldosterone levels. Twice daily treatment with quinapril&#xD;
      (40mg) lowered plasma PAI-1 levels during the expected peak time. In a second study of twice&#xD;
      daily quinapril compared to twice daily losartan in normotensive subjects both only had a&#xD;
      modest effect on plasma PAI-1 levels. A third study helped to explain this finding. In a&#xD;
      crossover study, hypertensive subjects received daily spironolactone or hydrochlorothiazide&#xD;
      (HCTZ) in a randomized fashion. Plasma PAI-1 levels were increased after HCTZ treatment, but&#xD;
      not significantly changed from baseline with spironolactone treatment. Spironolactone&#xD;
      treatment, however, resulted in significantly higher aldosterone levels. The correlation&#xD;
      between plasma aldosterone and PAI-1 that was observed at baseline and with HCTZ treatment&#xD;
      was not observed in the spironolactone arm, suggesting that the endogenous relationship&#xD;
      between aldosterone and PAI-1 can be disrupted by mineralocorticoid receptor antagonism.&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Completed</overall_status>
  <start_date>April 2007</start_date>
  <completion_date type="Actual">April 2010</completion_date>
  <primary_completion_date type="Actual">April 2010</primary_completion_date>
  <phase>Phase 4</phase>
  <study_type>Interventional</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <allocation>Randomized</allocation>
    <intervention_model>Crossover Assignment</intervention_model>
    <primary_purpose>Basic Science</primary_purpose>
    <masking>Triple (Participant, Care Provider, Investigator)</masking>
  </study_design_info>
  <primary_outcome>
    <measure>Plasminogen Activator Inhibitor-1 (PAI-1) Levels</measure>
    <time_frame>Baseline</time_frame>
    <description>baseline PAI-1 levels prior to drug administration</description>
  </primary_outcome>
  <primary_outcome>
    <measure>Plasminogen Activator Inhibitor-1 (PAI-1) Levels</measure>
    <time_frame>after 6 weeks on Eplerenone</time_frame>
    <description>PAI-1 levels after Eplerenone 50mg daily for 2 weeks then 100mg daily for 4 weeks. Time of administration varied in the arms, either morning or night time dosing.</description>
  </primary_outcome>
  <number_of_arms>2</number_of_arms>
  <enrollment type="Actual">21</enrollment>
  <condition>Metabolic Syndrome X</condition>
  <arm_group>
    <arm_group_label>Daytime then nightime dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 50mg, by mouth, daily, in the evening x 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks.</description>
  </arm_group>
  <arm_group>
    <arm_group_label>Nighttime then daytime dosing</arm_group_label>
    <arm_group_type>Experimental</arm_group_type>
    <description>Eplerenone - 50mg, by mouth, daily, in the evening x 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks then patients cross over to 50mg, by mouth, daily, in the morning x 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks.</description>
  </arm_group>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone (Morning)</intervention_name>
    <description>Eplerenone - 50mg, by mouth, daily, in the morning x 2 weeks followed by 4 weeks at 100mg.&#xD;
100mg, by mouth, daily, in the morning x 4 weeks then patients cross over to 100mg, by mouth, daily, in the evening x another 4 weeks.</description>
    <arm_group_label>Daytime then nightime dosing</arm_group_label>
    <arm_group_label>Nighttime then daytime dosing</arm_group_label>
    <other_name>Inspra</other_name>
  </intervention>
  <intervention>
    <intervention_type>Drug</intervention_type>
    <intervention_name>Eplerenone (Night-time)</intervention_name>
    <description>Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg</description>
    <arm_group_label>Daytime then nightime dosing</arm_group_label>
    <arm_group_label>Nighttime then daytime dosing</arm_group_label>
    <other_name>Inspra</other_name>
  </intervention>
  <eligibility>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  Age18-65&#xD;
&#xD;
          -  Metabolic Syndrome (3 or more of the following):&#xD;
&#xD;
               1. Blood pressure 130/85 or greater&#xD;
&#xD;
               2. Central obesity (Waist - Male &gt; 40&quot;, Female &gt; 35&quot;)&#xD;
&#xD;
               3. Fasting glucose ≥ 110 mg/dl&#xD;
&#xD;
               4. Low HDL (Male &lt; 40 mg/dl, Female &lt; 50 mg/dl)&#xD;
&#xD;
               5. Elevated Triglycerides (&gt; 150 mg/dl)&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Cigarette Use&#xD;
&#xD;
          -  Renal insufficiency&#xD;
&#xD;
          -  Coronary Artery Disease&#xD;
&#xD;
          -  Diabetes&#xD;
&#xD;
          -  Blindness&#xD;
&#xD;
          -  Cerebrovascular Disease&#xD;
&#xD;
          -  Secondary hypertension (renal artery stenosis, pheo, etc.)&#xD;
&#xD;
          -  RAAS disease (Primary Aldosteronism, etc.)&#xD;
&#xD;
          -  Other chronic illness (cancer, autoimmune or liver disease)&#xD;
&#xD;
          -  Pregnancy&#xD;
&#xD;
          -  Anemia (Hgb &lt; 12 mg/dl)&#xD;
&#xD;
          -  Evening or Night Shift work&#xD;
&#xD;
          -  Transmeridian travel in previous 6 months&#xD;
&#xD;
          -  History of sleep disorders&#xD;
&#xD;
          -  Hypokalemia (serum potassium &lt; 3.5 milliequivalent (mEq/L)&#xD;
&#xD;
          -  Hyperkalemia (serum potassium &gt; 5.5 mEq/L&#xD;
&#xD;
          -  Reported hypersensitivity to HCTZ or eplerenone&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>65 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>James A Muldowney, III, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Vanderbilt University</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Vanderbilt University Medical Center</name>
      <address>
        <city>Nashville</city>
        <state>Tennessee</state>
        <zip>37232-8802</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>January 2019</verification_date>
  <study_first_submitted>August 9, 2007</study_first_submitted>
  <study_first_submitted_qc>August 10, 2007</study_first_submitted_qc>
  <study_first_posted type="Estimate">August 13, 2007</study_first_posted>
  <results_first_submitted>March 16, 2017</results_first_submitted>
  <results_first_submitted_qc>January 31, 2019</results_first_submitted_qc>
  <results_first_posted type="Actual">February 1, 2019</results_first_posted>
  <last_update_submitted>January 31, 2019</last_update_submitted>
  <last_update_submitted_qc>January 31, 2019</last_update_submitted_qc>
  <last_update_posted type="Actual">February 1, 2019</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>Vanderbilt University Medical Center</investigator_affiliation>
    <investigator_full_name>James Muldowney</investigator_full_name>
    <investigator_title>Assistant Professor</investigator_title>
  </responsible_party>
  <keyword>Metabolic syndrome</keyword>
  <keyword>Aldosterone inhibitor</keyword>
  <keyword>Diurnal drug regimen</keyword>
  <keyword>PAI-1 levels</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Metabolic Syndrome</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Eplerenone</mesh_term>
  </intervention_browse>

  <clinical_results>

    <participant_flow>
      <pre_assignment_details>1 participant withdrew prior to randomization</pre_assignment_details>
      <group_list>
        <group group_id="P1">
          <title>Eplerenone: Morning Administration Then Evening</title>
          <description>Eplerenone - 50mg, by mouth, daily, in the morning for 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks&#xD;
Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg</description>
        </group>
        <group group_id="P2">
          <title>Eplerenone: Evening Administration Then Morning</title>
          <description>Eplerenone 50mg, by mouth, daily, in the evening for 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks&#xD;
Eplerenone - 50mg, by mouth, daily, in the morning for 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks</description>
        </group>
      </group_list>
      <period_list>
        <period>
          <title>Overall Study</title>
          <milestone_list>
            <milestone>
              <title>STARTED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="9"/>
                <participants group_id="P2" count="11"/>
              </participants_list>
            </milestone>
            <milestone>
              <title>NOT COMPLETED</title>
              <participants_list>
                <participants group_id="P1" count="0"/>
                <participants group_id="P2" count="0"/>
              </participants_list>
            </milestone>
          </milestone_list>
        </period>
      </period_list>
    </participant_flow>

    <baseline>
      <group_list>
        <group group_id="B1">
          <title>Eplerenone: Morning Administration Then Evening</title>
          <description>Eplerenone - 50mg, by mouth, daily, in the morning for 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks&#xD;
Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg</description>
        </group>
        <group group_id="B2">
          <title>Eplerenone: Evening Administration Then Morning</title>
          <description>Eplerenone 50mg, by mouth, daily, in the evening for 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks&#xD;
Eplerenone - 50mg, by mouth, daily, in the morning for 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks</description>
        </group>
        <group group_id="B3">
          <title>Total</title>
          <description>Total of all reporting groups</description>
        </group>
      </group_list>
      <analyzed_list>
        <analyzed>
          <units>Participants</units>
          <scope>Overall</scope>
          <count_list>
            <count group_id="B1" value="9"/>
            <count group_id="B2" value="11"/>
            <count group_id="B3" value="20"/>
          </count_list>
        </analyzed>
      </analyzed_list>
      <measure_list>
        <measure>
          <title>Age</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>&lt;=18 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Between 18 and 65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="9"/>
                    <measurement group_id="B2" value="11"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
                <category>
                  <title>&gt;=65 years</title>
                  <measurement_list>
                    <measurement group_id="B1" value="0"/>
                    <measurement group_id="B2" value="0"/>
                    <measurement group_id="B3" value="0"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Sex: Female, Male</title>
          <units>Participants</units>
          <param>Count of Participants</param>
          <class_list>
            <class>
              <category_list>
                <category>
                  <title>Female</title>
                  <measurement_list>
                    <measurement group_id="B1" value="5"/>
                    <measurement group_id="B2" value="5"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
                <category>
                  <title>Male</title>
                  <measurement_list>
                    <measurement group_id="B1" value="4"/>
                    <measurement group_id="B2" value="6"/>
                    <measurement group_id="B3" value="10"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
        <measure>
          <title>Region of Enrollment</title>
          <units>participants</units>
          <param>Number</param>
          <class_list>
            <class>
              <title>United States</title>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="B1" value="10"/>
                    <measurement group_id="B2" value="10"/>
                    <measurement group_id="B3" value="20"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </measure_list>
    </baseline>

    <outcome_list>
      <outcome>
        <type>Primary</type>
        <title>Plasminogen Activator Inhibitor-1 (PAI-1) Levels</title>
        <description>baseline PAI-1 levels prior to drug administration</description>
        <time_frame>Baseline</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Morning Administration Then Evening</title>
            <description>Eplerenone - 50mg, by mouth, daily, in the morning for 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks&#xD;
Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg</description>
          </group>
          <group group_id="O2">
            <title>Eplerenone: Evening Administration Then Morning</title>
            <description>Eplerenone 50mg, by mouth, daily, in the evening for 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks&#xD;
Eplerenone - 50mg, by mouth, daily, in the morning for 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plasminogen Activator Inhibitor-1 (PAI-1) Levels</title>
          <description>baseline PAI-1 levels prior to drug administration</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Deviation</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="9"/>
                <count group_id="O2" value="11"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="41.5" spread="17.9"/>
                    <measurement group_id="O2" value="42.9" spread="10.5"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
      <outcome>
        <type>Primary</type>
        <title>Plasminogen Activator Inhibitor-1 (PAI-1) Levels</title>
        <description>PAI-1 levels after Eplerenone 50mg daily for 2 weeks then 100mg daily for 4 weeks. Time of administration varied in the arms, either morning or night time dosing.</description>
        <time_frame>after 6 weeks on Eplerenone</time_frame>
        <group_list>
          <group group_id="O1">
            <title>Eplerenone: Morning Administration</title>
            <description>Eplerenone - 50mg, by mouth, daily, in the morning for 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks</description>
          </group>
          <group group_id="O2">
            <title>Eplerenone: Night-time Administration</title>
            <description>Eplerenone 50mg, by mouth, daily, in the evening for 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks</description>
          </group>
        </group_list>
        <measure>
          <title>Plasminogen Activator Inhibitor-1 (PAI-1) Levels</title>
          <description>PAI-1 levels after Eplerenone 50mg daily for 2 weeks then 100mg daily for 4 weeks. Time of administration varied in the arms, either morning or night time dosing.</description>
          <units>ng/ml</units>
          <param>Mean</param>
          <dispersion>Standard Error</dispersion>
          <analyzed_list>
            <analyzed>
              <units>Participants</units>
              <scope>Measure</scope>
              <count_list>
                <count group_id="O1" value="20"/>
                <count group_id="O2" value="20"/>
              </count_list>
            </analyzed>
          </analyzed_list>
          <class_list>
            <class>
              <category_list>
                <category>
                  <measurement_list>
                    <measurement group_id="O1" value="39.9" spread="4.0"/>
                    <measurement group_id="O2" value="40.4" spread="3.8"/>
                  </measurement_list>
                </category>
              </category_list>
            </class>
          </class_list>
        </measure>
      </outcome>
    </outcome_list>

    <reported_events>
      <group_list>
        <group group_id="E1">
          <title>Eplerenone: Morning Administration Then Evening</title>
          <description>Eplerenone - 50mg, by mouth, daily, in the morning for 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks&#xD;
Eplerenone - 50mg, by mouth, daily in the evening x 2 weeks followed by 4 weeks at 100mg</description>
        </group>
        <group group_id="E2">
          <title>Eplerenone: Evening Administration Then Morning</title>
          <description>Eplerenone 50mg, by mouth, daily, in the evening for 2 weeks followed by 100mg, by mouth, daily, in the evening x 4 weeks&#xD;
Eplerenone - 50mg, by mouth, daily, in the morning for 2 weeks followed by 100mg, by mouth, daily, in the morning x 4 weeks</description>
        </group>
      </group_list>
      <serious_events>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, all-cause mortality</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
              <event>
                <sub_title>Total, serious adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </serious_events>
      <other_events>
        <frequency_threshold>0</frequency_threshold>
        <category_list>
          <category>
            <title>Total</title>
            <event_list>
              <event>
                <sub_title>Total, other adverse events</sub_title>
                <counts group_id="E1" subjects_affected="0" subjects_at_risk="9"/>
                <counts group_id="E2" subjects_affected="0" subjects_at_risk="11"/>
              </event>
            </event_list>
          </category>
        </category_list>
      </other_events>
    </reported_events>

    <certain_agreements>
      <pi_employee>Principal Investigators are NOT employed by the organization sponsoring the study.</pi_employee>
      <restrictive_agreement>There is NOT an agreement between Principal Investigators and the Sponsor (or its agents) that restricts the PI's rights to discuss or publish trial results after the trial is completed. </restrictive_agreement>
    </certain_agreements>
    <point_of_contact>
      <name_or_title>James Muldowney</name_or_title>
      <organization>Vanderbilt University Medical Center</organization>
      <phone>615-936-1720</phone>
      <email>james.muldowney@vanderbilt.edu</email>
    </point_of_contact>
  </clinical_results>
</clinical_study>

